IFIH1 and clinically amyopathic dermatomyositis: Generally, these features fit well with those of previously reported CADM with positive anti‐MDA5 antibody.14, 15 The prognosis of anti‐MDA5‐positive CADM patients is unfavorable, with a 40% mortality rate, attributed mostly to the rapid progression of ILD.15 In our study, we found that the patients in cluster C were more likely to receive aggressive immunosuppressive therapy (46.4%), which reflected the physicians’ clinical judgements of a poorer outcome in this cluster.